Richard Ratei

Berlin, BE, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 27 publications

Automated identification of cell populations in flow cytometry data with transformers.

Automated identification of cell populations in flow cytometry data with transformers.

Journal: Computers in biology and medicine

Published: December 14, 2021

An Extensive Quality Control and Quality Assurance (QC/QA) Program Significantly Improves Inter-Laboratory Concordance Rates of Flow-Cytometric Minimal Residual Disease Assessment in Acute Lymphoblastic Leukemia: An I-BFM-FLOW-Network Report.

An Extensive Quality Control and Quality Assurance (QC/QA) Program Significantly Improves Inter-Laboratory Concordance Rates of Flow-Cytometric Minimal Residual Disease Assessment in Acute Lymphoblastic Leukemia: An I-BFM-FLOW-Network Report.

Journal: Cancers

Published: September 30, 2021

Author Correction: Loss-of-function uORF mutations in human malignancies.

Author Correction: Loss-of-function uORF mutations in human malignancies.

Journal: Scientific reports

Published: January 29, 2021

Treatment and outcome of IG-MYC+ neoplasms with precursor B-cell phenotype in childhood and adolescence.

Treatment and outcome of IG-MYC+ neoplasms with precursor B-cell phenotype in childhood and adolescence.

Journal: Leukemia

Published: May 30, 2019

Automated Flow Cytometric MRD Assessment in Childhood Acute B- Lymphoblastic Leukemia Using Supervised Machine Learning.

Automated Flow Cytometric MRD Assessment in Childhood Acute B- Lymphoblastic Leukemia Using Supervised Machine Learning.

Journal: Cytometry. Part A : the journal of the International Society for Analytical Cytology

Published: March 04, 2019

Flow-cytometric minimal residual disease monitoring in blood predicts relapse risk in pediatric B-cell precursor acute lymphoblastic leukemia in trial AIEOP-BFM-ALL 2000.

Flow-cytometric minimal residual disease monitoring in blood predicts relapse risk in pediatric B-cell precursor acute lymphoblastic leukemia in trial AIEOP-BFM-ALL 2000.

Journal: Pediatric blood & cancer

Published: June 07, 2018

Expression of CD56 defines a distinct subgroup in childhood T-ALL with inferior outcome. Results of the ALL-BFM 2000 trial.

Expression of CD56 defines a distinct subgroup in childhood T-ALL with inferior outcome. Results of the ALL-BFM 2000 trial.

Journal: British journal of haematology

Published: March 28, 2018

International cooperative study identifies treatment strategy in childhood ambiguous lineage leukemia.

International cooperative study identifies treatment strategy in childhood ambiguous lineage leukemia.

Journal: Blood

Published: December 19, 2017

NOTCH1 mutation, TP53 alteration and myeloid antigen expression predict outcome heterogeneity in children with first relapse of T-cell acute lymphoblastic leukemia.

NOTCH1 mutation, TP53 alteration and myeloid antigen expression predict outcome heterogeneity in children with first relapse of T-cell acute lymphoblastic leukemia.

Journal: Haematologica

Published: April 01, 2017

Loss-of-function uORF mutations in human malignancies.

Loss-of-function uORF mutations in human malignancies.

Journal: Scientific reports

Published: March 07, 2017

Flow-cytometric immunophenotyping in clinical diagnostics

Flow-cytometric immunophenotyping in clinical diagnostics

Journal: Deutsche medizinische Wochenschrift (1946)

Published: October 18, 2016

AIEOP-BFM consensus guidelines 2016 for flow cytometric immunophenotyping of Pediatric acute lymphoblastic leukemia.

AIEOP-BFM consensus guidelines 2016 for flow cytometric immunophenotyping of Pediatric acute lymphoblastic leukemia.

Journal: Cytometry. Part B, Clinical cytometry

Published: June 03, 2016

Showing 1-12 of 27

Last Updated: 09/26/2026